CXCL9 and Alzheimer disease: Conversely, we observed reductions in the levels of IL-17A, IL-17F, and MIG (detected at high levels in patients with AD), which are predicted to be associated with an alleviation of AD symptoms [16,18,19,20,21,22,23,24].